Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

BRITE-Eye: An integrated discovery engine for CNS therapeutic targets driven by high throughput genetic screens, functional readouts in human neurons, and machine learning

Award Number: R44MH135521
ORGANIZATION: NATIONAL INSTITUTE OF MENTAL HEALTH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/19/2023
PERIOD OF PERFORMANCE END DATE: 08/31/2025

Group Awards By:

View Award Description

BRITE-Eye: An integrated discovery engine for CNS therapeutic targets driven by high throughput genetic screens, functional readouts in human neurons, and machine learning - Project Summary Neurological disorders affect millions of patients worldwide and represent a major unmet medical need. Recent progress on developing new classes of central nervous system (CNS) therapeutics has lagged compared to other disease areas. A key obstacle in the CNS drug discovery process has been a need for cellular models, assays, and technologies that can more reliably assess disease-relevant neurophysiological parameters in a human cellular context at the level of individual neurons and synapses, with the scale and resolution to capture the complexity and variability of these systems. We propose to address this need through the integration of three key technologies – (i) our high throughput BRITETM platform for all-optical physiology in human neurons, which achieves single-cell and single-action-potential resolution with a throughput of ~500,000 neurons per day per instrument; (ii) genomic screens using CRISPR nuclease to disrupt gene function; (iii) machine learning for identification of fingerprints that represent complex physiological phenotypes with single-cell resolution. This Phase II program includes four key objectives. 1) Establish CRISPRn screening conditions in human neurons. We will select 20 candidate target genes, including epilepsy and neurodevelopmental targets to further optimize assay conditions compatible with all-optical physiology phenotyping, including timing of genetic disruption and concentration of CRISPRn/gRNA components for effective knockdown of gene targets. 2) Build deep-learning- powered analytical tools for single-cell phenotyping. We will use deep neural networks to learn a compact vector representation of neuronal behavior after pharmacological intervention that leverages our single cell resolution measurements and accommodates potential heterogeneity in the population of neurons. 3) Identify genetic modulators of neuronal function using a genome-wide CRISPRn screen. We will combine experimental conditions and analytical models established in Aims 1-2 to carry out a genome-wide CRISPRn screen (>18,000 gene targets) with arrayed gRNA libraries in wild-type human iPSC-excitatory neurons. We will identify gene targets whose downregulation leads to significant changes in functional parameters. Potential hits and specificity of target knockdown will be confirmed in independent rounds using single gRNA and qPCR and immunoblotting assays. 4) Predict and validate phenotypic rescue in a human iPSC-neuronal model of Fragile X Syndrome. Finally, we will assess the predictive value of the functional fingerprints developed in Aim 3 to generate a candidate list of gene targets that can rescue (suppress) phenotypic parameters we have identified in a human cellular model of the neurodevelopmental disorder, Fragile X syndrome. We will modulate the expression of these potential genetic suppressors with CRISPRn in FMR1-/y iPSC-neurons and benchmark phenotypic rescue using genetic re-introduction of FMRP. Successful completion of the proposed work has potential to yield a new understanding of the molecular architecture of human neurophysiology and a platform for novel therapeutic target identification focused on the molecular basis for modulation of neurophysiological disease mechanisms.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2024	QUIVER BIOSCIENCE INC.	150 CAMBRIDGEPARK DRIVE 5TH FLOOR	CAMBRIDGE	MA	02140	MIDDLESEX	USA	Mental Health Research Grants	000	2	12/17/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $1,278,054 )
2024	2024	QUELLTX INC	179 SIDNEY ST	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Mental Health Research Grants	001	2	8/1/2024	NON-COMPETING CONTINUATION	$1,278,054
2024	2023	QUELLTX INC	179 SIDNEY ST	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Mental Health Research Grants	000	1	6/6/2024	NEW	$0
														Subtotal = $1,278,054

Issue Date FY: 2023 ( Subtotal = $1,721,943 )
2023	2023	QUELLTX INC	179 SIDNEY ST	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Mental Health Research Grants	000	1	9/19/2023	NEW	$1,721,943
														Subtotal = $1,721,943

Grand Total All Awards = $2,999,997

Top

All Categories

About

Search

Reports

Data Submission

Award Information

BRITE-Eye: An integrated discovery engine for CNS therapeutic targets driven by high throughput genetic screens, functional readouts in human neurons, and machine learning

Award Number: R44MH135521

ORGANIZATION: NATIONAL INSTITUTE OF MENTAL HEALTH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/19/2023

PERIOD OF PERFORMANCE END DATE: 08/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer